

Multifocal Colonic Ulcerations: An Unusual Presentation of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Vítor Macedo Silva^{a-c} Marta Freitas^{a-c} Pedro Boal Carvalho^{a-c}
Francisca Dias de Castro^{a-c} José Cotter^{a-c}

^aDepartment of Gastroenterology, Hospital da Senhora da Oliveira, Guimarães, Portugal;

^bLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal;

^cICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal

Keywords

Lymphoma · MALT · Colonic neoplasms · Colonoscopy · Oncology

Abstract

Introduction: Mucosa-associated lymphoid tissue (MALT) lymphoma is relatively uncommon and accounts for only 5% of all non-Hodgkin lymphomas. The most common site of extranodal involvement is the gastrointestinal (GI) tract, with most cases affecting the stomach (up to 75% of all GI MALT lymphomas). Colonic disease occurs in only 2.5% of cases, most commonly manifesting as a single polypoid lesion on endoscopic evaluation. **Case Presentation:** We present the case of a 61-year-old woman whose colonoscopy (after a positive fecal occult blood test as part of colorectal cancer screening) revealed superficially ulcerated pseudo-polypoid lesions in the ascending proximal colon and hepatic flexure; microscopical and immunohistochemical analysis of the tissue sample was compatible with MALT lymphoma. Staging computed tomography showed concomitant nodular pulmonary lesions, the largest being located in the superior left lobe and 34 mm in size. Due to the disseminated state of the

disease, systemic treatment with bendamustine and rituximab was initiated. Up to the time of submitting this paper, the patient was still asymptomatic and under chemotherapy treatment. **Conclusion:** With this case report, we aim to demonstrate the diversity of presentation of MALT lymphoma as well as its less typical locations; gastroenterologists should have an awareness of these and a low suspicion threshold.

© 2021 Sociedade Portuguesa de Gastreterologia
Published by S. Karger AG, Basel

Ulcerações multifocais do colon: uma apresentação atípica de linfoma de tecido linfóide associado à mucosa (MALT)

Palavras Chave

Linfoma · MALT · Neoplasias do cólon · Colonoscopia · Oncologia

Resumo

Introdução: O linfoma de tecido linfóide associado à mucosa (MALT) é relativamente incomum, representando

5% de todos os linfomas não-Hodgkin. O local de envolvimento extra-nodal mais comum é o trato gastrointestinal, com a maioria dos casos a afetar o estômago (até 75% de todos os linfomas de MALT gastrointestinais). O envolvimento primário do cólon ocorre apenas em 2.5% dos doentes, sendo mais comumente observado como lesão polipoide única em avaliação endoscópica. **Apresentação de caso:** Apresentamos o caso de uma mulher de 61 anos, cuja colonoscopia após pesquisa de sangue oculto nas fezes positiva evidenciou lesões pseudo-polipoides superficialmente erodidas no cólon ascendente proximal e no ângulo hepático. A análise histológica (microscópica e imunohistoquímica) de ambas as lesões foi concordante e compatível com linfoma de MALT. A tomografia computadorizada de estadiamento revelou lesões nodulares pulmonares concomitantes, a maior localizada no lobo superior esquerdo com cerca de 34 mm. Devido ao estado disseminado da doença, a doente foi proposta para terapêutica sistêmica com bendamustina e rituximab. À data de submissão deste caso, a doente continuava assintomática e sob tratamento com quimioterapia. **Conclusão:** Com este caso clínico pretendemos salientar a diversidade de apresentações possíveis no linfoma de MALT, bem como as suas localizações mais atípicas para as quais todos os gastroenterologistas devem estar atentos e com baixo limiar de suspeição.

© 2020 Sociedade Portuguesa de Gastroenterologia
Publicado por S. Karger AG, Basel

Introduction

Non-Hodgkin lymphomas (NHL) are a common hematologic malignancy, but only 5–15% of the cases can be classified as marginal-zone lymphomas (MZL). Over the last 2 decades, the overall incidence of MZL has increased, possibly related to improvements in pathological diagnosis [1]. Up to two-thirds of these present as an extranodal neoplasm, such as mucosa-associated lymphoid tissue (MALT) lymphoma, with the stomach being the most common site of involvement, due to chronic inflammation associated with *Helicobacter pylori* infection which is present in up to 90% of the patients [2]. Ocular adnexa, the lungs, and the salivary glands follow. Disease of the colon occurs in only 2.5% of cases [3]. In contrast to its gastric counterpart, the pathophysiology of colonic MALT lymphoma is not well understood, resulting in limited therapeutic options [4].

We present a rare case of MALT lymphoma with colon involvement exhibiting unusual endoscopic findings.

Case Report

A 61-year-old woman was referred to our unit after a positive fecal occult blood test (FOBT) for colorectal cancer screening. Her medical history was significant for chronic obstructive pulmonary disease and total gastrectomy for unknown reasons >20 years prior to admission. Premedication included the inhaled bronchodilators salbutamol and formoterol. There was no family history of digestive tract neoplasms. Prior to being evaluated at our center, the patient had undergone a colonoscopy, with the report describing an ulcerated, irregular lesion on the ileocecal valve with an inconclusive histological sample. Upper endoscopy showed a total gastrectomy with no other relevant findings.

On admission, the patient denied any digestive symptoms such as abdominal pain, overt gastrointestinal (GI) bleeding, intestinal transit changes, or systemic symptoms like fever, weight loss, night sweats, and anorexia. Physical examination showed a soft, nondistended abdomen, with no tenderness and normal bowel sounds. No palpable lymph nodes were noted. Blood tests revealed normal hemoglobin, leukocyte count, iron parameters, haptoglobin, β_2 -microglobulin, C-reactive protein, and lactate dehydrogenase.

A decision was made to repeat colonoscopy with lesion sampling at our center. At this procedure, an area of irregular mucosa with approximately 15 mm adjacent to the ileocecal valve was observed (Fig. 1a). This lesion had a congestive appearance, with superficially ulcerated areas and a pseudo-polypoid component. On the hepatic flexure, additional areas of mucosa ranging from 5 to 10 mm with similar characteristics were seen (Fig. 1b). The remaining colon segments had no endoscopic abnormalities. The first endoscopic impression was of an ischemic or drug-induced colopathy, but the patient had neither a history of cardiovascular risk factors nor a regular consumption of drugs associated with colorectal mucosal disruption.

Separate biopsies were taken from both locations and presented similar results. Adding to the presence of fibrin and leukocyte exudates compatible with ulceration, the mucosa was also expanded by populations of atypical lymphoid cells (Fig. 2). Immunohistochemical stain of the biopsy specimens concluded that the neoplastic cells were positive for CD20 and CD43 and negative for CD3, CD5, CD10, cyclin D1, and CD23. These morphological and immunohistochemical characteristics are compatible with MALT extranodal marginal zone B cell lymphoma.

Thoracic, abdominal, and pelvic computed tomography (CT) without contrast (due to a known history of allergy) was performed. The images displayed many nodular lesions in both lungs, the largest located in the superior left lobe with a size of 31 × 34 mm (Fig. 3); biopsy revealed it as compatible with additional areas of MALT lymphoma involvement. There were no other lesions observed in the abdominal or pelvic plans including nodal involvement areas. Bone marrow biopsy was performed and showed no signs of disease infiltration. These areas of involvement classified this patient's lymphoma as a stage IV disease according to the Lugano staging system [5].

Due to the disseminated state of the disease, systemic treatment with bendamustine and rituximab was initiated. Concerning prognosis, this patient presented with a MALT-IPI index of 1, considered to correspond to an intermediate risk [6].

Up to the time this paper was submitted (5 months after the diagnostic colonoscopy), the patient is still asymptomatic and under chemotherapy treatment.

Fig. 1. **a** Endoscopic image of ileocecal valve lesion (white arrow). **b** Endoscopic image of hepatic flexure lesions (white arrows).





Fig. 2. Histological images. **a** Infiltration of the colonic mucosa by atypical lymphoid cells. HE. $\times 40$. **b** Immunohistochemical staining for cytokeratin AE1/AE3. $\times 40$. **c** Immunohistochemical staining for CD20. $\times 40$.

Fig. 3. Thoracic CT scan showing the larger pulmonary lesion in the superior left lobe (white arrows).



Discussion

MALT lymphomas were first described in the early 1980s as low-grade B cell neoplasms with extranodal presentation [7] and have now grown to become the third-most common B cell NHL, representing up to 9% of cases [8]. They have a predilection for the GI tract, with this pathological entity being most known for its gastric involvement. The pathophysiology behind this association

is firmly understood, as infection by *H. pylori* plays a pivotal role in the process [2]. The stomach is the primary location in 60–75% of patients [9], but a MALT lymphoma may also be located in the esophagus, small bowel, colon, or rectum [10, 11].

Two different pathways are proposed for overall MALT lymphoma development; one originates from normally present lymphoid tissue like Peyer patches in the gut, and the other results from acquired lymphoid tissue appearing

in response to inflammation after infections, autoimmune disorders, inflammatory bowel disease, and immunosuppression, none of which was present in this patient [12].

Colorectal disease is the least common GI location, resulting in a nonelucidated pathogenesis, since the classical risk factors for gastric MALT lymphoma, like *H. pylori* infection, do not play a similarly preponderant role [11]. However, in a recent review of the literature by Won et al. [12], about 20% of patients with MALT lymphoma affecting the colon and rectum had a positive test for *H. pylori* infection, indicating that this pathogen may partially influence the development of this disease, even in the large intestine. This does not seem to have been the case in our patient, as she had been submitted to total gastrectomy 2 decades before presentation. Other bacterial agents, such as *Borrelia afzelii*, *Campylobacter jejuni*, *Chlamydia psittaci*, and *Mycobacterium* spp., have been linked to the onset of MALT lymphoma, but none of them has a clearly reported association with colorectal disease [13].

Colon MALT lymphoma mostly affects individuals in their fifth to seventh decades, with a slight predominance in the female gender, in line with our case report [14]. This neoplasm is often asymptomatic and discovered incidentally on routine colonoscopy. Reported symptoms, if present, are abdominal pain, weight loss, diarrhea, constipation, hematochezia, or, in rare cases, a palpable abdominal mass [15]. Analytically, it can also be diagnosed after the presence of mild anemia or positive FOBT, as was the case of this patient.

On endoscopic examination, MALT lymphoma with colonic involvement has a diverse range of manifestations. The most common is the existence of a single polypoid lesion, but it can also appear as multiple polypoid lesions, or, even more rarely, as nodular or ulcerated lesions [16]. Our case faces the odds as it consisted of a doubly uncommon manifestation of the disease, presenting with multiple lesions and as an ulcer-like manifestation.

Location within the colon varies according to the series. In previous reports, most of the colorectal MALT lymphomas developed in the cecum or ascending colon, with >70% being proximal to the hepatic flexure [13], as was observed in our case. However, more recent series have indicated the rectum as the most commonly affected segment and accounting for 39% of cases [12].

According to the 2016 World Health Organisation Classification of Tumours of Haematopoietic and Lymphoid Tissues, the histology of MALT lymphoma comprises infiltration of the mucosa by monocytoid B cells, centrocyte-like cells, and small lymphocytes [8]. It is possible that epithelial lesions of >3 monocytoid lympho-

cytes even cause the distortion of mucosal glands. The immunohistochemical panel, according to the European Society of Medical Oncology guidelines, consists of mandatory positive staining for CD20 and obligatory negative staining for CD5, CD10, and cyclin D1. Negativity for IgD and the *Myd88* mutation is also suggested. CD23 may be negative or positive [17]. Our case matched all these requirements.

MALT lymphoma involving the colon may present with simultaneous lesions occurring at other sites in the GI tract, such as the stomach or the duodenum, which may be observed in up to 12% of the cases [12]. Synchronous lesions must be sought by performance of upper endoscopy, bone marrow biopsy, and thoracic and abdominal CT. Our patient underwent all of these procedures. Only the CT scan revealed disease involvement, showing nodular lesions on both lungs and a subsequent biopsy compatible with MALT lymphoma.

The majority of MALT lymphomas are of a low grade when first diagnosed. Extranodal MZL usually remain localized for a long period of time, but involvement of the lymph nodes or additional mucosal sites may be present at diagnosis, as was seen in this case. This disseminated form of the disease is particularly common in nongastric MALT lymphomas, being described in 25–50% of cases [18]. In previous reports, colorectal MALT lymphomas presented exclusively in the GI tract in around 70% of the patients [15], with disseminated extranodal involvement or concomitant nodal involvement seen in about 30% of the cases. MZL with lymph node or bone marrow involvement carry a worse prognosis, but the same is not verified in patients with involvement of multiple mucosal sites, as in our case [19].

Overall, colorectal MALT lymphomas carry a good prognosis compared to other lymphomas involving the colon and rectum, such as diffuse large B cell and T cell lymphomas, regardless of the initial stage of the disease [15]. Extranodal MZL-specific prognostic indices have been proposed, such as the MALT-IPI index [6], an accurate tool for both gastric and nongastric MALT lymphomas which classifies the patients as low-, intermediate- or high-risk. The 5-year event-free survival rate is significantly influenced by this index; however, it is still not a factor that influences the treatment decision. Our patient presented with a MALT-IPI index of 1 (age <70 years, normal lactate dehydrogenase, and an Ann Arbor classification IV), which predicts a 5-year event-free survival of 56% and an overall survival of 93%.

The classical gastric MALT lymphoma has better-known therapeutic options, as the mainstay of treatment

for localized disease consists of antibiotic treatment for *H. pylori* infection, with complete remission being achieved in 70–80% of the cases [20]. As for colon disease, the same cannot be applied as there is no current standardized treatment. Anti-infective therapy cannot be currently recommended for this setting. Radiotherapy is the preferred option for treating localized disease, but one must be aware of its possible long-term complications. Surgery has not been shown to achieve superior results when compared to less invasive approaches to extranodal MZL [21]. For patients who require systemic treatment (disseminated disease, contraindications, a failure to respond to local therapy, and histological transformation), chemotherapy, immunotherapy, or a combination of both, are all effective. Generally accepted pharmacological choices include either rituximab alone or in combination with other agents such as chlorambucil, bendamustine, or lenalidomide [17]. Since the pathophysiology of colon MALT lymphoma is still a matter of debate and therapeutic options are not as well-known as those for gastric disease, enrolling patients in clinical trials should be encouraged.

References

- 1 Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. *Blood*. 2016 Apr;127(17):2082–92.
- 2 Nakamura S, Yao T, Aoyagi K, Iida M, Fujishima M, Tsuneyoshi M. Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients. *Cancer*. 1997 Jan;79(1):3–11.
- 3 Chen PH, Lin YM, Yen HH. Primary mucosa-associated lymphoid tissue lymphoma of the colon. *Clin Gastroenterol Hepatol*. 2011 Aug;9(8):e74–5.
- 4 Hollie N, Asakrah S. MALT lymphoma of the colon: a clinicopathological review. *J Clin Pathol*. 2020 Jul;73(7):378–83.
- 5 Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. *Chin Clin Oncol*. 2015 Mar;4(1):5.
- 6 Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. *Blood*. 2017 Sep;130(12):1409–17.
- 7 Isaacson PG. Gastrointestinal lymphomas of T- and B-cell types. *Mod Pathol*. 1999 Feb;12(2):151–8.
- 8 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016 May;127(20):2375–90.
- 9 Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. *J Gastrointest Oncol*. 2012 Sep;3(3):209–25.
- 10 Hosaka S, Nakamura N, Akamatsu T, Fujisawa T, Ogiwara Y, Kiyosawa K, et al. A case of primary low-grade mucosa-associated lymphoid tissue (MALT) lymphoma of the esophagus. *Gut*. 2002 Aug;51(2):281–4.
- 11 Howell JM, Auer-Grzesiak I, Zhang J, Andrews CN, Stewart D, Urbanski SJ. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. *Can J Gastroenterol*. 2012 Jul;26(7):452–6.
- 12 Won JH, Kim SM, Kim JW, Park JH, Kim JY. Clinical features, treatment and outcomes of colorectal mucosa-associated lymphoid tissue (MALT) lymphoma: literature reviews published in English between 1993 and 2017. *Cancer Manag Res*. 2019 Sep;11:8577–87.
- 13 Seo SW, Lee SH, Lee DJ, Kim KM, Kang JK, Kim DW, et al. Colonic mucosa-associated lymphoid tissue lymphoma identified by chromoendoscopy. *World J Gastroenterol*. 2014 Dec;20(48):18487–94.
- 14 Abbas H, Niazi M, Makker J. Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Colon: A Case Report and a Literature Review. *Am J Case Rep*. 2017 May;18:491–7.
- 15 Jeon MK, So H, Huh J, Hwang HS, Hwang SW, Park SH, et al. Endoscopic features and clinical outcomes of colorectal mucosa-associated lymphoid tissue lymphoma. *Gastrointest Endosc*. 2018 Feb;87(2):529–39.
- 16 Matsumoto T, Shimizu M, Iida M, Amano K, Nakamura S, Fujishima M. Primary low-grade, B-cell, mucosa-associated lymphoid tissue lymphoma of the colorectum: clinical and colonoscopic features in six cases. *Gastrointest Endosc*. 1998 Nov;48(5):501–8.
- 17 Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, et al.; ESMO Guidelines Committee. Electronic address: clinical-guidelines@esmo.org. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2020 Jan;31(1):17–29.
- 18 Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). *CA Cancer J Clin*. 2016 Mar-Apr;66(2):153–71.
- 19 Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, et al.; International Extranodal Lymphoma Study Group. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. *Blood*. 2003 Apr;101(7):2489–95.
- 20 Wündisch T, Thiede C, Morgner A, Dempf A, Günther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. *J Clin Oncol*. 2005 Nov;23(31):8018–24.
- 21 Zucca E, Stathis A, Bertoni F. The management of nongastric MALT lymphomas. *Oncology (Williston Park)*. 2014 Jan;28(1):86–93.

Statement of Ethics

Written informed consent was obtained from the patient to publish this case report and any accompanying images.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

There was no funding.

Author Contributions

V.M.S. drafted the manuscript. M.F. performed the colonoscopy and collaborated in the manuscript draft. P.B.C. and F.D.C. revised the manuscript. J.C. critically revised the manuscript and approved the final version for submission.